|1.||Takaiwa, Fumio: 6 articles (01/2015 - 11/2007)|
|2.||Yang, Lijun: 4 articles (01/2015 - 11/2007)|
|3.||Wakasa, Yuhya: 3 articles (01/2015 - 11/2007)|
|4.||Takagi, Hidenori: 3 articles (01/2015 - 04/2009)|
|5.||Hirose, Sakiko: 3 articles (08/2010 - 11/2007)|
|6.||Hiroi, Takachika: 2 articles (01/2015 - 08/2010)|
|7.||Ogo, Yuko: 2 articles (01/2015 - 09/2014)|
|8.||Wang, Shuyi: 2 articles (09/2014 - 06/2013)|
|9.||Takahashi, Hideyuki: 2 articles (09/2014 - 06/2013)|
|10.||Ellis, Jason S: 2 articles (10/2011 - 04/2010)|
|1.||Seasonal Allergic Rhinitis (Hay Fever)
09/01/2014 - "Tree pollen chimera 7 (TPC7), a hypoallergenic Bet v 1 tolerogen against birch pollen allergy, induces the formation of novel, huge protein bodies (referred to as TPC7 bodies) in rice endosperm, and is accumulated in high level. "
01/01/2015 - "Concentrated protein body product derived from rice endosperm as an oral tolerogen for allergen-specific immunotherapy--a new mucosal vaccine formulation against Japanese cedar pollen allergy."
08/01/2010 - "Here, we generated transgenic rice seeds accumulating allergen-derived T cell epitopes, a model tolerogen for the control of pollen allergy, in either ER-derived protein body-I (PB-I) or protein storage vacuole protein body-II (PB-II). "
06/01/2013 - "Tree pollen chimera 7 (TPC7), a hypoallergenic Bet v 1 tolerogen against birch pollen allergy, was previously selected by DNA shuffling of 14 types of Fagales tree pollen allergens. "
04/01/2009 - "A 7Crp peptide composed of seven major human T cell epitopes derived from the Japanese cedar pollen allergens Cry j 1 and Cry j 2 is an ideal tolerogen for peptide immunotherapy against Japanese cedar pollinosis. "
09/01/1995 - "A 15-residue synthetic peptide flanking this region, CII 607-621, was found to effectively suppress arthritis when administered as a tolerogen. "
04/01/1995 - "This conclusion is further supported by the observation that an unodecapeptide representing CII 190-200 was just as effective as CII 181-209 in suppressing arthritis and anti-CII antibody response when tested as a tolerogen. "
08/01/1988 - "The fact that chick CII as tolerogen is quite effective in preventing arthritis in B10.RIII mice, while as immunogen it is very ineffective in inducing arthritis in this strain, may be interpreted as evidence for interaction between different epitopes on CII in the pathogenesis of CIA."
01/01/2002 - "Based on their production of Th2 cytokines, these data suggest that T regulatory cells expressing activation and memory markers are induced by the tolerogen and may exert their influence via cytokines to protect the animals from the induction of arthritis."
07/01/1993 - "Both peptides suppressed the incidence of arthritis whereas no other peptide used as a tolerogen significantly altered the course of the disease. "
|3.||Delayed Hypersensitivity (Hypersensitivity, Type IV)
01/01/1986 - "Previous studies using a murine delayed hypersensitivity model demonstrated that 5-methyl-3-pentadecylcatechol (5-Me-PDC) is an epicutaneous tolerogen to the parent compound and a weak sensitizer to itself. "
02/01/1990 - "Because no expansion in the clone size of tolerogen-specific precursors of Ag-specific IL-2-secreting T cells (pIL-2) is observed among tolerant animals, and because the pIL-2 cells from tolerant mice are incapable of differentiating into cytotoxic and delayed hypersensitivity effector cells, we further propose that the precociously primed pIL-4 cells function as "suppressor" cells, helping to maintain the tolerant state."
05/01/1983 - "In this report, we examine tolerance (hyporesponsiveness) and suppression of delayed hypersensitivity (DH) to herpes simplex virus (HSV) in mice, using two different forms of tolerogen: HSV particles and HSV-infected spleen cells. "
11/01/1995 - "[Characterization of tolerogen-producing cells and lymphoid tissues where self-tolerance is induced--a study on allogeneic bone marrow chimeras established with spontaneous leukemia prone mice]."
09/01/2000 - "Selection for tumor resistance among the progeny from a cross between SAg-negative donor and SAg- positive recipient strains revealed a strict correlation between loss of the endogenous SAg tolerogen, rescue of Vbeta6 T cells from SAg-mediated deletion, and leukemia resistance. "
|2.||Proteins (Proteins, Gene)
|3.||Immunoglobulin E (IgE)
|6.||Member 3 Group F Nuclear Receptor Subfamily 1
|7.||Hepatitis B e Antigens
|9.||T-Lymphocyte Epitopes (Epitopes, T Lymphocyte)
|10.||Immunoglobulin G (IgG)